#GoldenCross $CALA at 6.38 R11 HiLo 68% T1Y 12 none fwdPE -4.0 DIV N/A #Calithera #stocks #trading #finance #market

2019-03-14
56 Views

Golden Cross detected for CALA (Calithera Bioscience) at the close price of 6.38. Trading at a 68 % level between the 52week High (7.70) and 52week Low (3.55). The average analyst 1-year target price is 12.0 with an average none and a score of 0.0.

Golden Cross 11 % CALA 6.38
Calithera Bioscience HiLo 68.2 %
Support 5.12 Resistance 6.38
50DMA 4.92 200DMA 4.91
52week high 7.70 52week low 3.55
10DMA 5.80 20DMA 5.66
100 Mean 4.86
Volume 417771 AvgDayVol 183806
MarketCap 247784528 EBITDA -56776000
Revenue 22254000 PE 0.00
P2S 11.13 P2B 0.00
Dividend 0.00 Div Ex-Date

Further research links:

Marketwatch Yahoo Finance Google Finance StockTwits

You may be interested

#Levermann #ASIA  #BigCap #Buy WK20 $0688.HK (4)
Asia, BigCap, Bull
24 views
Asia, BigCap, Bull
24 views

#Levermann #ASIA #BigCap #Buy WK20 $0688.HK (4)

Andreas Aigner - 2019-05-20

TOP CAPs for #Levermann #ASIA #BigCap #Buy WK20 $0688.HK (4)

#Levermann #EU  #BigCap #Buy WK20 $ALV.DE (7), $EOAN.DE (5), $LGEN.L (4), $HNR1.DE (4)
BigCap, Bull, Europe
21 views
BigCap, Bull, Europe
21 views

#Levermann #EU #BigCap #Buy WK20 $ALV.DE (7), $EOAN.DE (5), $LGEN.L (4), $HNR1.DE (4)

Andreas Aigner - 2019-05-20

TOP CAPs for #Levermann #EU #BigCap #Buy WK20 $ALV.DE (7), $EOAN.DE (5), $LGEN.L (4), $HNR1.DE (4)

#Levermann #EU  #BigCap #Sell WK20 $DTE.DE (0), $BAYN.DE (-4), $ADS.DE (0), $BMW.DE (-2), $CON.DE (0), $EVK.DE (0)
Bear, BigCap, Europe
25 views
Bear, BigCap, Europe
25 views

#Levermann #EU #BigCap #Sell WK20 $DTE.DE (0), $BAYN.DE (-4), $ADS.DE (0), $BMW.DE (-2), $CON.DE (0), $EVK.DE (0)

Andreas Aigner - 2019-05-20

TOP CAPs for #Levermann #EU #BigCap #Sell WK20 $DTE.DE (0), $BAYN.DE (-4), $ADS.DE (0), $BMW.DE (-2), $CON.DE (0), $EVK.DE (0)

Leave a Comment

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

We use Cookies to improve our Site. Your are agreeing to this by continuing to use our Site.